Tong Ren Tang Technologies Co Ltd
HKEX:1666
Tong Ren Tang Technologies Co Ltd
Revenue
Tong Ren Tang Technologies Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
T
|
Tong Ren Tang Technologies Co Ltd
HKEX:1666
|
Revenue
ÂĄ7.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Revenue
ÂĄ12.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
![]() |
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Revenue
ÂĄ10.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
15%
|
CAGR 10-Years
23%
|
|
![]() |
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Revenue
ÂĄ28B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
14%
|
|
![]() |
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Revenue
ÂĄ40B
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Revenue
ÂĄ2.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
Tong Ren Tang Technologies Co Ltd
Glance View
Tong Ren Tang Technologies Co., Ltd. engages in the production and distribution of Chinese medicine. The company is headquartered in Beijing, Beijing. The company went IPO on 2000-10-31. The Company’s subsidiaries include Beijing Tong Ren Tang Technologies (Tangshan) Co., Ltd, Beijing Tong Ren Tang Century Advertising Co., Limited and Beijing Tong Ren Tang International Natural-Pharm Co., Ltd.. Through its subsidiaries, the Company is also engaged in cultivating, purchasing and selling Chinese medicinal raw materials.
See Also
What is Tong Ren Tang Technologies Co Ltd's Revenue?
Revenue
7.3B
CNY
Based on the financial report for Dec 31, 2024, Tong Ren Tang Technologies Co Ltd's Revenue amounts to 7.3B CNY.
What is Tong Ren Tang Technologies Co Ltd's Revenue growth rate?
Revenue CAGR 5Y
10%
Over the last year, the Revenue growth was 7%. The average annual Revenue growth rates for Tong Ren Tang Technologies Co Ltd have been 10% over the past three years , 10% over the past five years .